Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amphastar PharmaceuticalsAMPH -0.58%82 EV-to-EBIT is 9.84 as of Jul. 18, 2026, which is 34% below its 10-year median of 14.92. GuruFocus rates AMPH with a GF Score™ of 82/100 and a GF Value™ of $48.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 71.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Amphastar Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $1,268.9 Mil.
Amphastar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $128.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals EV-to-EBIT Related Terms
Amphastar Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's EV-to-EBIT falls into.
Amphastar Pharmaceuticals's current Enterprise Value is $1,265.0 Mil.
Amphastar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $128.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a EV-to-EBIT of 9.84 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amphastar Pharmaceuticals and its competitors. This is 34% below median its historical median of 14.92. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #194 out of 689 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Amphastar Pharmaceuticals' EV-to-EBIT too high?
Amphastar Pharmaceuticals' current EV-to-EBIT of 9.84 is 34% below median its 10-year median of 14.92. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Amphastar Pharmaceuticals' value of 9.84 is 37.4% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #194 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' EV-to-EBIT compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #194 out of 689 companies for EV-to-EBIT. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBIT is 15.73. Amphastar Pharmaceuticals' value of 9.84 is 37.4% below this benchmark. While the company's 10-year median is 14.92 vs. the industry median of 15.73, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current EV-to-EBIT of 9.84 is 37.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current EV-to-EBIT is 9.84, which is 34% below median its own 10-year median of 14.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.94, compared to a current price of $19.75 — trading 59.7% below its estimated fair value. The current EV-to-EBIT is 9.84, which is 34% below median its 10-year median of 14.92 and 37.4% below the Drug Manufacturers industry median of 15.73. Amphastar Pharmaceuticals' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current EV-to-EBIT is 9.84 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $19.75 is trading 59.7% below its estimated GF Value™ of $48.94.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
EV-to-EBIT: 9.84 (34% below median its 10-year median of 14.92)
GF Value™: $48.94 vs. price of $19.75 (59.7% below fair value)
Industry Position: 37.4% below the Drug Manufacturers median (#194 of 689)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
82GF Score
Get the complete analysis for AMPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
